Creating RNA-based CAR T cells to treat autoimmune disorders
Manufacturing RNA-based CAR T cells to combat autoantibody-associated autoimmune disorders (AAAD)
This study is testing a new type of treatment using RNA to help people with autoimmune diseases by training special immune cells to target and remove the harmful cells that cause problems, and it aims to see how well this approach works and how it affects patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cartesian Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Gaithersburg, UNITED STATES) |
| Project ID | NIH-11110351 on NIH RePORTER |
What this research studies
This research focuses on developing a novel RNA-based cell therapy aimed at treating autoimmune diseases where the body's immune system mistakenly attacks its own tissues. The approach involves using chimeric antigen receptor T cells (CAR-T) that are engineered to target and eliminate dysfunctional plasma cells responsible for producing harmful autoantibodies. Unlike traditional CAR-T therapies that use DNA, this method employs RNA to provide a safer, temporary expression of the CAR, potentially reducing side effects and improving patient outcomes. The study will also analyze biomarkers from patients who receive this innovative therapy to assess its effectiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with neurological autoimmune diseases such as myasthenia gravis or neuromyelitis optica.
Not a fit: Patients with autoimmune disorders not affecting the nervous system or those who do not respond to CAR-T therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for patients suffering from autoimmune disorders.
How similar studies have performed: While RNA-based therapies are a relatively novel approach, previous research has shown promise in using RNA for other therapeutic applications, indicating potential for success in this area.
Where this research is happening
Gaithersburg, UNITED STATES
- Cartesian Therapeutics, INC. — Gaithersburg, United States (Active)
Researchers
- Principal investigator: Jewell, Christopher M — Cartesian Therapeutics, INC.
- Study coordinator: Jewell, Christopher M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.